      <!-- SECTION 4: SOLUTION -->
      <section id="solution" class="investor-section">
          <div class="investor-content-card">
              <h2 class="investor-h2">We Build the Regulatory-Grade Software 'Brain' (SaMD plug-in)</h2>
              
              <p class="investor-p">PatientCentricCare.AI is the <strong>Safety OS‚Ñ¢</strong>‚Äîa software-as-a-medical-device (SaMD) platform that transforms general-purpose humanoid robots into FDA-compliant medical devices.</p>
              
              <h3 class="investor-h3">Three Core Differentiators:</h3>
              
              <div class="investor-differentiator-list">
                  <div class="investor-differentiator-item">
                      <div class="differentiator-number">1</div>
                      <div class="differentiator-content">
                          <h4>SaMD Classification</h4>
                          <p>We're software, not hardware‚Äîenabling faster regulatory approval and scalable deployment</p>
                      </div>
                  </div>
                  
                  <div class="investor-differentiator-item">
                      <div class="differentiator-number">2</div>
                      <div class="differentiator-content">
                          <h4>Physician-in-the-Loop (AIITL)</h4>
                          <p>All critical care decisions require physician approval before execution, eliminating autonomous liability risk</p>
                      </div>
                  </div>
                  
                  <div class="investor-differentiator-item">
                      <div class="differentiator-number">3</div>
                      <div class="differentiator-content">
                          <h4>Hardware-Agnostic</h4>
                          <p>Our Safety OS plugs into any humanoid platform (Unitree, Boston Dynamics, etc.), making us the universal standard</p>
                      </div>
                  </div>
              </div>
              
              <div class="investor-integration-box">
                  <h4>üîó Integration</h4>
                  <p>Seamless EHR connectivity (Epic, Cerner, Allscripts) ensures real-time patient data access with HIPAA compliance and full audit trails.</p>
              </div>
          </div>
      </section>
      
      <!-- SECTION 5: WHY NOW -->
      <section id="why-now" class="investor-section" style="background: #f8f9fa;">
          <div class="investor-content-card">
              <h2 class="investor-h2">The Regulatory Moat That Unlocks the $1T Healthcare Segment</h2>
              
              <p class="investor-p" style="text-align: center; font-size: 1.4rem; color: #E67E22; font-weight: 600; margin-bottom: 2rem;">
                  <strong>Regulation isn't our barrier‚Äîit's our moat.</strong>
              </p>
              
              <p class="investor-p">Think of the <strong>Humanoid Healthcare</strong> market as a <strong>massive reservoir of demand</strong> held back by a regulatory dam. Hardware companies can build robots, but they can't open the <strong>sluice gate</strong> to institutional <strong>healthcare</strong> buyers (hospitals, nursing homes, insurers) without FDA-compliant safety controls.</p>
              
              <p class="investor-p" style="text-align: center; font-size: 1.5rem; color: #2C3E50; font-weight: 600; margin: 2rem 0;">
                  We are the sluice gate.
              </p>
              
              <p class="investor-p">By solving the regulatory challenge first, we become the <strong>mandatory software layer</strong> that every humanoid healthcare platform must license. This creates a defensible moat that hardware competitors cannot replicate‚Äîthey build robots, we make them legally deployable.</p>
              
              <div class="investor-moat-box">
                  <h4>üèÜ First-Mover Advantage</h4>
                  <p>Once we establish the compliance standard, we become the de facto platform for the entire industry.</p>
              </div>
          </div>
      </section>
      
      <!-- SECTION 6: GO-TO-MARKET -->
      <section id="go-to-market" class="investor-section">
          <div class="investor-content-card">
              <h2 class="investor-h2">Dual-Track SaMD Pilots ($6M US + EU)</h2>
              
              <p class="investor-p">We are raising <strong>$6M in seed funding</strong> to execute parallel regulatory pilots in the world's two largest healthcare markets:</p>
              
              <div class="investor-table-container">
                  <table class="investor-table">
                      <thead>
                          <tr>
                              <th>Allocation</th>
                              <th>Region</th>
                              <th>Strategic Focus</th>
                          </tr>
                      </thead>
                      <tbody>
                          <tr>
                              <td><strong>$3M</strong></td>
                              <td><strong>United States</strong></td>
                              <td>FDA SaMD approval via Medical Alley (Minnesota) partnerships and leveraging the Harvard Medical School Network</td>
                          </tr>
                          <tr>
                              <td><strong>$3M</strong></td>
                              <td><strong>European Union</strong></td>
                              <td>CE Mark certification and pilot deployments in aging-population markets</td>
                          </tr>
                      </tbody>
                  </table>
              </div>
              
              <h3 class="investor-h3">Why Dual-Track?</h3>
              
              <div class="investor-why-list">
                  <div class="investor-why-item">
                      <span class="why-icon">‚úì</span>
                      <div>
                          <strong>De-risks regulatory uncertainty:</strong> Success in either market validates our approach
                      </div>
                  </div>
                  <div class="investor-why-item">
                      <span class="why-icon">‚úì</span>
                      <div>
                          <strong>First-mover advantage:</strong> Parallel execution captures both markets before competitors
                      </div>
                  </div>
                  <div class="investor-why-item">
                      <span class="why-icon">‚úì</span>
                      <div>
                          <strong>Defensible moat:</strong> Dual regulatory approvals create massive barriers to entry
                      </div>
                  </div>
              </div>
              
              <div class="investor-timeline-box">
                  <h4>‚è±Ô∏è Timeline</h4>
                  <p><strong>18-24 months</strong> to first pilot deployments and Pre-FDA Pilot & Research Partnership Fees (NRE) plus SaaS / Integration services.</p>
                  <p style="margin-top: 1rem;"><strong>Expect first commercial launch of SaMD certified Humanoid Healthcare by 2031 (US).</strong></p>
              </div>
          </div>
      </section>
